 |
 |
 |
| CIBRIM-T - Brimonidine Tartrate with Timolol Maleate |
|
||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||
| Cibrim-T (Brimonidine Tartrate0.2% /Timolol Maleate 0.5%) ophthalmic solution sterile, is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor (Topical Intraocular Pressure Lowering Agent) Pharmacology: Cibrim-T is comprised of two components: Brimonidine Tartrate and Timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Brimonidine Tartrate has a dual mechanism of action by reducing aqueous humor production and increasing non pressure dependent uveoscleral outflow. Timolol maleate is a beta 1 and beta 2 adrenergic receptor reduces aqueous humor production thus reduces increased intra ocular pressure. | ||||||||||||||||||||||||
| Indications | ||||||||||||||||||||||||
Cibrim-T indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; |
||||||||||||||||||||||||
| Dosage | ||||||||||||||||||||||||
| The recommended dose in adults is one drop of Cibrim-T in the affected eye (S) twice daily, approximately 12 hours apart. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. | ||||||||||||||||||||||||
| Contraindications | ||||||||||||||||||||||||
| Asthma / COPD Contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease, with sinus bradycardia; second or third degree atrioventricular block; overt cardiac; cardiogenic shock. Local hypersensitivity reactions have occurred following the use of different components of Brimonidine tartrate/Timolol maleate ophthalmic solution. Contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past. |
||||||||||||||||||||||||
| Precautions | ||||||||||||||||||||||||
| Pregnancy: Category C. Since there are no adequate and well-controlled studies in pregnant women, brimonidine – timolol fixed combination should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Timolol is excreted in human milk. It is not known if Brimonidine is excreted in human milk but is excreted in the milk of the lactating rat. Therefore, Brimonidine – Timolol fixed combination should not be used by women breast-feeding infants. Pediatric Use: Brimonidine Tartrate/Timolol Maleate ophthalmic solution is not recommended for use in children under the age of 2 years. Geriatric Use: No overall differences in safety and effectiveness have been observed between elderly and younger patients. |
||||||||||||||||||||||||
| Storage | ||||||||||||||||||||||||
| Store in a cool dry place protect from light. | ||||||||||||||||||||||||
| Presentation | ||||||||||||||||||||||||
| Cibrim-T Eye Drops: Vial of 5ml | ||||||||||||||||||||||||
